Association of IL6,IL18 and FH-125 in treatment resistant among patients with schizophrenia
DOI:
https://doi.org/10.36320/ajb/v12.i1.8149Keywords:
IL6, IL18, FH-125, treatment resistantAbstract
Background:
Schizophrenia is mental illness described by atypical behavior and a reduced ability to understanding truth. Symptom include false beliefs, confused thinking unclear or, hearing voice and other People do not, reduced emotional expression, social engagement and lack of motivation. Schizophrenia patient often have other mental health problems like depressive, anxiety, or substance-use disorders.
Methods:
During the period from January 2019 to May 2019, a total of 37 patients with TRS and 37 control without autoimmune disease non-pregnant were included in this study. All these parsons were attending the AL Hakeem General hospital, their ages grouped from (18-70) years. Male to Female ratio 1/1. Erythrocyte Sedimentation Rate (ESR), White Blood Cell Count to prove all participants in this study free from infectious disease for exclusion criteria. IL6, IL18 and FH-125 in serum samples were measured by (ELISA).
Downloads
References
Miller A, McEvoy J, Jeste D, et al. (2006)Treatment of chronic schizophrenia. In: Lieberman J, Stroup TS, Perkins D, eds. Textbook of Schizophrenia. Washington, DC: American Psychiatric Publishing; 2006:365-381.
Meltzer H, Kostacoglu A.(2001) Treatment-resistant schizophrenia. In: Lieberman J, Murray R, eds. Comprehensive Care of Schizophrenia: A Textbook of Clinical Management. London: Martin Dunitz; 2001:181-203.
Brenner HD, Merlo MC.2000 Definition of therapy-resistant schizophrenia and its assessment. Eur Psychiatry. 2000;10(suppl 1):11s-17s. DOI: https://doi.org/10.1016/0767-399X(96)80079-4
Andreasen NC, Carpenter WT Jr, Kane JM, et al.(2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449. DOI: https://doi.org/10.1176/appi.ajp.162.3.441
Pantelis C, Lambert TJ.2003 Managing patients with ‘‘treatment-resistant’’ schizophrenia. Med J Aust. 2003;178(suppl):S62-S66. DOI: https://doi.org/10.5694/j.1326-5377.2003.tb05310.x
Kinon BJ, Ahl J, Stauffer VL, et al.2004 Dose response and atypical antipsychotics in schizophrenia [published correction appears in CNS Drugs. 2004;18:1052]. CNS Drugs. 2004;18:597-616. . DOI: https://doi.org/10.2165/00023210-200418090-00005
Kirch DG.2003 Infection and autoimmunity as etiologic factors in schizophrenia A review and reappraisal. Schizophr Bull. 2003;19(2):355–370. [PubMed] [Google Scholar] DOI: https://doi.org/10.1093/schbul/19.2.355
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Ali kamil, Wasan Sami Shukur, Arafat H assan AL-Dujaili
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
